Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

576 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
Morel A, Brière J, Lamant L, Loschi M, Haioun C, Delarue R, Tournilhac O, Bachy E, Sonet A, Amorim S, Laurent C, Gaulard P, Tilly H, Sibon D. Morel A, et al. Among authors: briere j. Eur J Cancer. 2017 Sep;83:146-153. doi: 10.1016/j.ejca.2017.06.026. Epub 2017 Jul 20. Eur J Cancer. 2017. PMID: 28735072 Clinical Trial.
Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
Sibon D, Fournier M, Brière J, Lamant L, Haioun C, Coiffier B, Bologna S, Morel P, Gabarre J, Hermine O, Sonet A, Gisselbrecht C, Delsol G, Gaulard P, Tilly H. Sibon D, et al. Among authors: briere j. J Clin Oncol. 2012 Nov 10;30(32):3939-46. doi: 10.1200/JCO.2012.42.2345. Epub 2012 Oct 8. J Clin Oncol. 2012. PMID: 23045585
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.
Lamarque M, Bossard C, Contejean A, Brice P, Parrens M, Le Gouill S, Brière J, Bouabdallah R, Canioni D, Tilly H, Bouchindhomme B, Bachy E, Delarue R, Haioun C, Gaulard P. Lamarque M, et al. Among authors: briere j. Haematologica. 2016 Mar;101(3):e103-6. doi: 10.3324/haematol.2015.135400. Epub 2015 Dec 24. Haematologica. 2016. PMID: 26703966 Free PMC article. Clinical Trial. No abstract available.
Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma.
Jardin F, Delfau-Larue MH, Molina TJ, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Jais JP, Figeac M, Leroy K, Mareschal S, Salles GA, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Haioun C, Tilly H. Jardin F, et al. Among authors: briere j. Leuk Lymphoma. 2013 Sep;54(9):1898-907. doi: 10.3109/10428194.2013.767456. Epub 2013 Feb 18. Leuk Lymphoma. 2013. PMID: 23327290
Management and prognosis of 66 patients with B-cell non-Hodgkin lymphoma presenting with initial spinal cord compression: a French retrospective multicenter study.
Fleury I, Amorim S, Mounier N, Coiffier B, Dupuis J, Tilly H, Mazari MA, Filliatre L, Brière J, Brice P, de Kerviler E, Thieblemont C. Fleury I, et al. Among authors: briere j. Leuk Lymphoma. 2015 Jul;56(7):2025-31. doi: 10.3109/10428194.2014.977884. Epub 2014 Dec 17. Leuk Lymphoma. 2015. PMID: 25347431
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ, Canioni D, Copie-Bergman C, Recher C, Brière J, Haioun C, Berger F, Fermé C, Copin MC, Casasnovas O, Thieblemont C, Petrella T, Leroy K, Salles G, Fabiani B, Morschauser F, Mounier N, Coiffier B, Jardin F, Gaulard P, Jais JP, Tilly H. Molina TJ, et al. Among authors: briere j. J Clin Oncol. 2014 Dec 10;32(35):3996-4003. doi: 10.1200/JCO.2013.54.9493. Epub 2014 Nov 10. J Clin Oncol. 2014. PMID: 25385729 Clinical Trial.
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Copie-Bergman C, Cuillière-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, Salles G, Parrens M, Belhadj K, Fabiani B, Recher C, Petrella T, Ketterer N, Peyrade F, Haioun C, Nagel I, Siebert R, Jardin F, Leroy K, Jais JP, Tilly H, Molina TJ, Gaulard P. Copie-Bergman C, et al. Among authors: briere j. Blood. 2015 Nov 26;126(22):2466-74. doi: 10.1182/blood-2015-05-647602. Epub 2015 Sep 15. Blood. 2015. PMID: 26373676 Free article. Clinical Trial.
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study.
Dubois S, Viailly PJ, Mareschal S, Bohers E, Bertrand P, Ruminy P, Maingonnat C, Jais JP, Peyrouze P, Figeac M, Molina TJ, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Brière J, Petrella T, Canioni D, Fabiani B, Coiffier B, Delarue R, Peyrade F, Bosly A, André M, Ketterer N, Salles G, Tilly H, Leroy K, Jardin F. Dubois S, et al. Among authors: briere j. Clin Cancer Res. 2016 Jun 15;22(12):2919-28. doi: 10.1158/1078-0432.CCR-15-2305. Epub 2016 Jan 27. Clin Cancer Res. 2016. PMID: 26819451 Free article. Clinical Trial.
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B. Thieblemont C, et al. Among authors: briere j. J Clin Oncol. 2017 Aug 1;35(22):2473-2481. doi: 10.1200/JCO.2017.72.6984. Epub 2017 Apr 20. J Clin Oncol. 2017. PMID: 28426350 Clinical Trial.
576 results